Kim Y, Kim A, Lee S, Choi SH, Lee DY, Song JS, Lee H, Jang IJ, Yu KS. Pharmacokinetics, Safety, and Tolerability of Tedizolid Phosphate After Single-Dose Administration in Healthy Korean Male Subjects. Clin Ther. 2017. Sep;39(9):1849-1857, ePub 2017 Aug 31.

How can we increase the efficiency, accuracy, and speed of patient enrollment into clinical trials? Clinical trial investigators have long been suffering from the low yield, inaccuracy, and delay of patient enrollment. It was mainly because the current practice is labor-intensive and has to be done manually in most cases. For example, based on the eligibility criteria of a clinical trial, a clinical trial investigator or one of his/her staff (e.g., clinical research coordinator) has to go over the entire medical record of a potential patient by eyeballing many scattered fields, which is very much time-consuming while inefficient and inaccurate. A typical clinical trial protocol has an average number of 50 for the eligibility criteria, which can become easily many more up to ~100 in late phase clinical trials. Dr. Lee discussed this issue and how artificial intelligence-guideded deep learning could address it at a recent Bio-Nanomedicine Salon (August 31, 2017) co-sponsored by the Korean Society for Nanomedicine and the Seoul National University Bio-Max Institute. 

Yi S, An H, Lee H, Lee S, Ieiri I, Lee Y, Cho JY, Hirota T, Fukae M, Yoshida K, Nagatsuka S, Kimura M, Irie S, Sugiyama Y, Shin DW, Lim KS, Chung JY, Yu KS, Jang IJ. Korean, Japanese, and Chinese populations featured similar genes encoding drug-metabolizing enzymes and transporters: a DMET Plus microarray assessment. Pharmacogenetics and genomics. 2014;24(10):477-485.

Lee H, Jang I-J, Yu K-S, Choi J, Oh B-H. A Population Pharmacokinetic Analysis of Fimasartan, a Selective Angiotensin II Receptor Antagonist, in Healthy Caucasian Subjects and Korean Patients With Hypertension. Clinical Pharmacology in Drug Development. 2013;2(2):162-72. doi: 10.1002/cpdd.10.

Lee H, Kim KS, Chae SC, Jeong MH, Kim DS, Oh BH. Ambulatory Blood Pressure Response to Once-Daily Fimasartan: An 8-Week, Multicenter, Randomized, Double-Blind, Active-Comparator, Parallel-Group Study in Korean Patients With Mild To Moderate Essential Hypertension. Clin Ther. 2013;35(9):1337-49. doi: 10.1016/j.clinthera.2013.06.021.